NIH SBIR Grant Received
Madeleine Pharmaceuticals, Inc. announced today that the National Heart, Lung and Blood Institute has awarded the company a $2 million grant under the Small Business Innovation Research (SBIR) program. The funds will be used by Madeleine to support its clinical programs to further the development of MP3167 as the recombinant biologic form of human proANP 31-67 and formulated as Vastiras® for intravenous or Vastiras®XT for subcutaneous administration as a co-therapy in the treatment of acute heart failure (AHF) patients. ...